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Background: Hodgkin’s lymphoma (HL) is a rare malignancy which often presents with lymphadenopathy and
classic “B symptoms” of weight loss, fever, and night sweats. Additional masses or nodes could easily be presumed
to be a result of the initial diagnosis. On the other hand, adult rhabdomyosarcoma is a rare malignancy presenting
with a new mass in a patient with previous diagnosis of Hodgkin’s lymphoma. In both cases, a tissue diagnosis
should be obtained to appropriately confirm the diagnosis.
Case presentation: We present a case of a 64-year-old male who presents with right axillary lymphadenopathy,
diagnosed as Hodgkin’s lymphoma. He subsequently developed left inguinal lymphadenopathy without the classic
B symptoms of HL. Excisional biopsy revealed rhabdomyosarcoma. Stage III Hodgkin’s lymphoma (lymph node
involvement on both sides of the diaphragm) is not commonly seen without typical B symptoms. Once the
diagnosis of two primary malignancies is made, the dilemma becomes determining the treatment course. In the
case of Hodgkin’s lymphoma and rhabdomyosarcoma, there is some overlap in the chemotherapeutic regimen and
use of radiation.
Conclusions: This case illustrates the importance of careful examination of Hodgkin’s lymphoma patients and
consideration of additional tissue diagnoses in atypical presentations of new masses or lymphadenopathy on the
opposite side of the diaphragm.
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Hodgkin’s lymphoma (HL) is an uncommon malignancy
of the lymphatic system, with an incidence of 2.5 per
100,000 [1]. It is well known to have a favorable progno-
sis, with a 5-year survival greater than 85 % and is thus
viewed as a potentially curable disease. There are five
histologic types currently described: nodular sclerosing
(most common), mixed cellularity, lymphocyte rich (best
prognosis), lymphocyte depleted (worst prognosis), and
nodular lymphocyte predominant. With the exception of
nodular lymphocyte predominant, all of these are char-
acterized by the presence of Reed-Sternberg (RS) cells
(typically B lymphocytes with CD 15 and CD 30 antigen* Correspondence: pxiao@tbh.org
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genetic component, commonly involves the mediastinum
and has CD20 antigen positivity.
Rhabdomyosarcoma (RMS) is a malignant tumor of
striated muscle similar to other high-grade soft tissue
sarcomas. It is the most common soft tissue sarcoma in
children (90 % of cases are diagnosed under 25 years of
age; 60–70 % of these are diagnosed under 10 years of
age) but a rare diagnosis in adults, with only an approxi-
mated 400 new cases in the USA each year [2]. Even
more rare is the diagnosis of “lymphadenopathic” RMS,
with only four prior cases described in the literature
[3–5]. Overall 5-year survival is poor compared to that
of HL, at 40 % [6]. Head and neck is the most common
anatomic location for these tumors. Five histologic types
are described: embryonal (most common), alveolar (worst
prognosis; commonly found in the extremities, trunk,is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 2 Immunohistochemical stain result reveals that RS cells are
positive for CD30 (immunoperoxidase stain ×20)
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cell embryonal, and anaplastic/undifferentiated [7]. Here,
we report a case of lymphadenopathic rhabdomyosar-
coma discovered in a patient with concurrent diagnosis
of Hodgkin’s lymphoma.
Case presentation
A 64-year-old Hispanic male presented to an outpatient
surgical setting at an inner-city community hospital com-
plaining of a newly discovered right axillary mass. The
patient had no past medical or surgical history other than
a left inguinal hernia repair performed 6 years prior for a
reducible, asymptomatic, left inguinal hernia. On physical
examination, the patient was noted to have a large, firm,
irregular, fixed, non tender mass in the right axilla, con-
sistent with a pathologic lymph node. He denied any
constitutional or B symptoms. He also denied any
weight loss, sick contacts, or recent travel. The patient
was offered a short course of oral antibiotic therapy
and was asked to return to the office in 2 weeks. When
the patient returned, the mass had slightly increased in
size. The decision was made to perform a right axillary
lymph node excisional biopsy. Microscopic examination
revealed scattered Reed-Sternberg (RS) or mummified
cells mixed with reactive inflammatory cells within fibrous
nodular background (Fig. 1). Immunohistochemical stain
results revealed that RS cells were positive for CD15
and CD30 (Fig. 2). The final pathology was reported
as Hodgkin’s lymphoma, nodular sclerosing type.
He was immediately referred to a hematologist/oncolo-
gist, and the patient was prepared to initiate chemo-
therapy. Various tumor markers, hepatitis panel, and
HIV testing were all negative. During this time, the
patient developed right epitrochlear lymphadenopathy
discovered by the oncologist. When seen again by theFig. 1 Microscopic examination reveals scattered Reed-Sternberg
(RS) or mummified cells mixed with reactive inflammatory cells
within fibrous nodular background (HE ×40)surgeon during a postoperative visit, the patient com-
plained of left scrotal pain with an associated left inguinal
mass, which he attributed to a recurrence of his previously
repaired left inguinal hernia. Upon close examination, it
was determined that the patient had left inguinal
lymphadenopathy, with characteristics similar to the
right axillary contents that were previously excised. The
oncologist, once notified of this finding, requested a
PET/CT scan. The scan revealed multiple enlarged
right subclavian, right axillary, and left inguinal lymph
nodes with moderate to significant FDG uptake. Based
on the nature of Hodgkin’s lymphoma, the recommen-
dation was made for an excisional biopsy of the left
inguinal lymph node due to the low likelihood of the
mass having the same HL origin (as would be more
likely with non-Hodgkin’s lymphoma).
A left inguinal lymph node excisional biopsy was per-
formed concurrently with placement of a left subclavian
Mediport. Grossly, the excised mass had a similar ap-
pearance to the right axillary lymph nodes removed
2 months earlier. It was an encapsulated, flesh colored
structure. Unexpectedly, the microscopic examination
revealed thin fibrous septae surrounded by small round
blue cells with an alveolar growth pattern. Immunohisto-
chemical and molecular studies confirmed the diagnosis
of rhabdomyosarcoma, alveolar type (Fig. 3). The patho-
logic slides were sent to a tertiary center and reviewed
for a second opinion, and the diagnosis was concurred.
The dilemma now faced is this: with two primary neo-
plasms, which one should be treated first and what
modalities of treatment would be most effective? Given
that this presentation is exceedingly rare, the patient was
referred to a highly specialized tertiary cancer center in
order to provide the best multidisciplinary approach to
this oncologic dilemma.
Fig. 3 Microscopic examination reveals thin fibrous septae surrounded
by small round blue cells with an alveolar growth pattern (HE ×20)
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Hodgkin’s lymphoma typically presents as painless lymph-
adenopathy. The so called B symptoms, which include
weight loss, fever, and night sweats, may be present and
implicate a poorer prognosis. Due to mediastinal involve-
ment, the nodular sclerosing type may present with chest
pain, cough, and shortness of breath. Often, a plethora of
diagnostic modalities aid in the diagnosis of Hodgkin’s
lymphoma, but ultimately, a tissue diagnosis is needed.
This is usually obtained surgically with an excisional
lymph node biopsy, as intact morphology is required for
an accurate diagnosis. The one exception to this is in head
and neck masses, where a fine needle aspiration (FNA)
may be pursued in order to rule out squamous cell carcin-
oma, which is very common in this anatomic location.
Once the diagnosis is made, a clinical stage is deciphered,
in order to orchestrate the treatment plan.
Hodgkin’s lymphoma can be described in four stages
as follows: stage I (a single lymph node area or single
extranodal site), stage II (two or more lymph node areas
on the same side of the diaphragm), stage III (lymph
node areas on both sides of the diaphragm), and stage
IV (disseminated or multiple involvement of the extra-
nodal organs). Four treatments options are available
depending on the nature of the disease: radiation
therapy, induction chemotherapy, salvage chemotherapy,
and hematopoietic stem cell transplantation. An example
of an induction chemotherapeutic regimen is cyclo-
phosphamide, doxorubicin, vincristine, and prednisone
(CHOP) [8]. When induction chemotherapy fails, or
the patient experiences relapse, a salvage chemothera-
peutic regimen such as ifosfamide, carboplatin, and
etoposide (ICE) can be initiated. Of note, HIV testing is
obtained in all HL patients, as HAART therapy signifi-
cantly improves outcomes in HIV positive patients with
Hodgkin’s lymphoma [7].Rhabdomyosarcoma typically presents as a mass or area
of localized swelling, and less than half of these patients
present with pain. However, symptoms can be specific to
the anatomic location of the lesion (e.g., cranial nerve com-
pression in head/neck tumors invading the skull base).
Diagnosis is made with a surgical biopsy (usually an inci-
sional biopsy). CT and MRI are helpful for planning surgical
resection, as well as planning routes and doses for potential
radiation therapy post operatively. Locoregional and meta-
static disease can be investigated with a bone marrow
biopsy, chest CT scan, technetium diphosphonate bone scan,
and even a lumbar puncture (for parameningeal primaries).
Mainstay therapy for rhabdomyosarcoma is surgical resec-
tion. High-risk histology and advanced stage may warrant
chemotherapy with or without radiation. For example, non-
metastatic alveolar rhabdomyosarcoma is usually treated
with the vincristine, dactinomycin, and cyclophosphamide
(VAC) protocol with the addition of radiation therapy [9].
Specifically relevant to this case, our patient initially
presented with two groups of enlarged lymph nodes on
the same side of the diaphragm and did not present with
B symptoms. He subsequently developed involvement of
a new group of lymph nodes on the other side of the
diaphragm (left inguinal) without development of B
symptoms. This was a rare presentation which raised the
suspicion of the oncologist, prompting a second excisional
biopsy. Specific to this case of Hodgkin’s lymphoma with
synchronous rhabdomyosarcoma (alveolar type), overlap-
ping treatment is available, thus making treatment options
less cumbersome. Margin negative (R0) resection is the
goal for the rhabdomyosarcoma. Given its aggressive
histology and the possibility of incomplete resection, che-
moradiation will likely be pursued. The CHOP induction
chemotherapeutic regimen for Hodgkin’s lymphoma has
some degree of overlap with the VAC protocol for rhabdo-
myosarcoma (vincristine being used for both). The chal-
lenge for the chemotherapist is the dose frequencies and
potential toxicities that these patients may experience.Conclusions
Patients with Hodgkin’s lymphoma that present with a
second primary tumor usually do so as a complication of
chemoradiation. Cancer screening is conducted regularly
in HL patients receiving treatment. However, presenting
with Hodgkin’s lymphoma and a second primary tumor
simultaneously is exceedingly rare and poorly described in
the literature. This can be a challenging diagnosis to make,
and clinicians must be aware that such entities exist.
When synchronous masses are present, or a new mass is
discovered in a patient with Hodgkin’s lymphoma prior to
treatment, one must be careful not to assume that they
are the same entity. When in doubt, a tissue diagnosis
should be pursued.
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